Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Ghrelin and LEAP-2: Rivals in energy metabolism.
Trends Pharmacol. Sci. 39, 685-694 (2018)
Liver-expressed antimicrobial peptide 2 (LEAP-2), the endogenous noncompetitive allosteric antagonist of the growth hormone secretagogue receptor 1a (GHSR1a), was recently identified as a key endocrine factor regulating systemic energy metabolism. This antagonist impairs the ability of ghrelin to activate GHSR1a and diminishes ghrelin-induced Ca2+ release in vitro. The physiological relevance of the molecular LEAP-2-GHSR1a interaction was subsequently demonstrated in vivo. LEAP-2 is therefore a promising therapeutic target in the treatment of obesity and other metabolic diseases. Here, we discuss not only the current understanding of LEAP-2 in metabolic regulation, but also the potential of this peptide in the treatment of obesity and other diseases that involve dysregulation of the ghrelin system.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Gh ; Ghsr1a ; Leap-2 ; Food Intake ; Ghrelin ; Metabolic Syndrome; Des-acyl Ghrelin; Hormone Secretagogue Receptor; Healthy Older-adults; Diet-induced Obesity; Growth-hormone; Food-intake; Double-blind; Weight-loss; Glucose-metabolism; Gastric Bypass
ISSN (print) / ISBN
0165-6147
e-ISSN
1873-3735
Quellenangaben
Volume: 39,
Issue: 8,
Pages: 685-694
Publisher
Cell Press
Publishing Place
Amsterdam
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Obesity (IDO)